Glaxo's Lotronex Risk-Management Program Emphasizes Appropriate Use
Executive Summary
Glaxo Wellcome is proposing an "appropriate use" campaign as the focus of its risk-management plan for Lotronex, the company told FDA's Gastrointestinal Drugs Advisory Committee June 27.
You may also be interested in...
Rx Safety Cmte.’s Holmboe Sees Communication As Key To Risk Management
Yale University's Eric Holmboe, MD, will be taking his second look at risk-management proposals for GlaxoSmithKline's Lotronex during the inaugural meeting of FDA's Drug Safety & Risk Management Subcommittee
Rx Safety Cmte.’s Holmboe Sees Communication As Key To Risk Management
Yale University's Eric Holmboe, MD, will be taking his second look at risk-management proposals for GlaxoSmithKline's Lotronex during the inaugural meeting of FDA's Drug Safety & Risk Management Subcommittee
GSK Lotronex To Be Reviewed By FDA Drug Safety Cmte. In April
FDA's Drug Safety & Risk Management Subcommittee will review the safety of GlaxoSmithKline's withdrawn irritable bowel syndrome agent Lotronex (alosetron) on April 23